Indian Pharma Companies Overseas: Zydus Eyes Sri Lanka Plant
Indian pharma companies overseas: Zydus plans a $20M-plus Sri Lanka plant with a local partner, operations from 2028. What it shows and what it does not.
Indian Pharma Companies Overseas: Zydus Eyes Sri Lanka Plant
Indian pharma companies overseas: Zydus plans a $20M-plus Sri Lanka plant with a local partner, operations from 2028. What it shows and what it does not.
New Celiac Disease Drugs Get a Bold ANB033 Result
New celiac disease drugs: First Tracks says ANB033 protected the gut in a 32-patient trial. See the 2027 roadmap, the risks and what is unknown.
Gilead Cancer Drug Pipeline Gets Bold Bet With Vir
The Gilead cancer drug pipeline adds three early Vir T-cell engagers. $90M upfront, up to about $1.88B in total. How the deal works and what is unknown.
mRNA Cancer Immunotherapy Setback: BNT113 Misses Endpoint
An mRNA cancer immunotherapy, BioNTech’s BNT113, missed its PFS goal in head and neck cancer. Overall survival is still being assessed. What it means.
Anti-Diabetic Drugs Market Posts Strong Growth in India
The anti-diabetic drugs market in India grew about 21% in September per one dataset and 16.1% per another. What drove it, including GLP-1 generics.
Biopharma SHAKTI Gets a Strong Start With 25 Trial Sites
Biopharma SHAKTI gets a 25-site clinical trial pilot as NIPER Raebareli and AstraZeneca India sign an MoU. What the pilot tests and what is undisclosed.
Coronary Stent Quality Under Review: Critical Test for Makers
Coronary stent quality is under government review in India. What tighter oversight could mean for makers and hospitals, and what is still unverified.
Perjeta Biosimilar Pebrilzo Gets Strong Boost After Settlement
A Perjeta biosimilar gets dates: Biocon says its Genentech settlement allows Pebrilzo in the EU and UK in Q1 2027 and the US in Q3 2028, subject to approvals.
Injectable Drug Contamination: Par Health Issues a Second Particulate Recall in a Week
Injectable drug contamination: Par Health recalls 22 argatroban lots days after two Brevital lots. A side-by-side look at both notices and open questions.
